# Aligo Innovation

> Aligo Innovation is a VC fund backing Biotechnology and Manufacturing. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 7
- Last investment: Jun 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/valeo-management-l-p
- X (Twitter): https://twitter.com/AligoInnovation
- Website: http://www.aligo.ca/en/

Aligo Innovation is a university research commercialization company in Quebec arising from the merger of Valeo Management and MSBI Valorisation. Aligo is dedicated to commercializing the intellectual property assets of its partner institutions.

## Contacts

5 contacts available for Aligo Innovation. Shizune tracks 1 team members at Aligo Innovation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aligo-innovation?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 29% |
| Manufacturing | 2 | 29% |
| Battery | 1 | 14% |
| Medical | 1 | 14% |
| Software | 1 | 14% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 29% |
| Pre-Seed | 1 | 14% |
| Series A | 1 | 14% |
| Funding Round | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Pierre des Lierres | Director of Business Development | 1 | https://shizune.co/investors/profile/pierre-des-lierres |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Calogy Solutions | Calogy Solution is a developer of thermal management technologies designed to assist in electric transportation applications. The company's technologies include thermal and CFD calculations for electronics thermal management, custom-designed compact liquid cooling, heat pipes, and vapor chambers and a wide range of thermal characterization,testing and validation services by exposing microelectronic components to various temperature conditions, enabling clients to identify and thereafter rectify the thermal challenges in their products. | $1.2M | Pre-Seed | Jun 01, 2020 |  |
| Laurent Pharmaceuticals | Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical-stage, orally-active drug candidate. The company has a clinical-stage drug development program (LAU-7b) that addresses the compromised immune-inflammatory response in Cystic Fibrosis (CF), a critical but still enigmatic pathogenic pathway leading to pulmonaryinsufficiency in CF patients.Laurent Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. |  |  | Oct 25, 2018 |  |
| SPARK Microsystems | SPARK Microsystems is a fabless semiconductor company that is leading the way towards ultra-low power wireless communications for the Internet of Things revolution. With its patented technologies, SPARK Microsystems will bring to market a high performance wireless transceiver that allows for orders of magnitude improved power consumption andlatency while providing higher data rates than competing technologies. For more information, please visit www.sparkmicro.com. | $1.3M | Seed | Nov 14, 2017 |  |
| Ovensa | Ovensa provides nanomedicine technology platforms, which deliver targeted oral therapy with mucosal and brain-barrier crossing properties. Ovensa focuses on developing personalized treatments for cancer and neurodegenerative diseases and on preventing antibiotic resistance. | $1.4M | Seed | Sep 12, 2017 |  |
| Ovensa | Ovensa provides nanomedicine technology platforms, which deliver targeted oral therapy with mucosal and brain-barrier crossing properties. Ovensa focuses on developing personalized treatments for cancer and neurodegenerative diseases and on preventing antibiotic resistance. | $530K | Seed | Jun 08, 2016 |  |
| Laurent Pharmaceuticals | Laurent Pharmaceuticals is a private biopharmaceutical company developing a clinical-stage, orally-active drug candidate. The company has a clinical-stage drug development program (LAU-7b) that addresses the compromised immune-inflammatory response in Cystic Fibrosis (CF), a critical but still enigmatic pathogenic pathway leading to pulmonaryinsufficiency in CF patients.Laurent Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. |  |  | Mar 17, 2016 |  |
| wrnch | wrnch is a computer vision / deep learning software engineering company based in Montréal, Canada, a renowned hub for AI, special effects and game technology.A profitable startup, wrnch was founded by Dr. Paul Kruszewski, a successful serial AI entrepreneur (with already two successful exits); was incubated by deep tech incubatorTandemLaunch, and is supported by knowledgeable and pragmatic investors including Mark Cuban. | $1.3M | Series A | Feb 26, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 4 deals together
- [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital) — VC Fund, 2 deals together
- [Cystic Fibrosis Foundation](https://shizune.co/investors/profile/the-cystic-fibrosis-foundation) — VC Fund, 2 deals together
- [Ecofuel](https://shizune.co/investors/profile/ecofuel) — VC Fund, 1 deal together
- [gr0k Technologies](https://shizune.co/investors/profile/gr0k-technologies) — VC Fund, 1 deal together
- [Groupe Roski](https://shizune.co/investors/profile/groupe-roski) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [CleanTech VC Funds in Canada](https://shizune.co/investors/cleantech-vc-funds-canada)

## FAQ

### What does Aligo Innovation invest in?

Aligo Innovation invests primarily in Biotechnology, Manufacturing and Battery startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aligo Innovation?

Public channels for Aligo Innovation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aligo Innovation?

The team at Aligo Innovation includes Pierre des Lierres (Director of Business Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co